[微笑]_老虎社区_美港股上老虎

StaceyLiew
2021-11-09

[微笑]

Biohaven falls 15% on apparent disappointment that Pfizer deal isn't a buyout

Shares of Biohaven Pharmaceuticals(NYSE:BHVN)are down 15% in premarket trading apparently because so

Biohaven falls 15% on apparent disappointment that Pfizer deal isn't a buyout

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":847088292,"tweetId":"847088292","gmtCreate":1636468385865,"gmtModify":1636468386949,"author":{"id":3584067862408237,"idStr":"3584067862408237","authorId":3584067862408237,"authorIdStr":"3584067862408237","name":"StaceyLiew","avatar":"https://static.tigerbbs.com/0d96094b3b57d3cc339a5fa471709239","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":25,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[微笑]&nbsp;</span></p></body></html>","htmlText":"<html><head></head><body><p><span>[微笑]&nbsp;</span></p></body></html>","text":"[微笑]","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/847088292","repostId":1122943951,"repostType":4,"repost":{"id":"1122943951","kind":"news","pubTimestamp":1636468144,"share":"https://www.laohu8.com/m/news/1122943951?lang=&edition=full","pubTime":"2021-11-09 22:29","market":"us","language":"en","title":"Biohaven falls 15% on apparent disappointment that Pfizer deal isn't a buyout","url":"https://stock-news.laohu8.com/highlight/detail?id=1122943951","media":"seekingalpha","summary":"Shares of Biohaven Pharmaceuticals(NYSE:BHVN)are down 15% in premarket trading apparently because so","content":"<p>Shares of Biohaven Pharmaceuticals(NYSE:BHVN)are&nbsp;down 15%&nbsp;in premarket trading apparently because some investors are disappointed that a Pfizer(NYSE:PFE)deal to commercialize Nurtec ODT wasn't a buyout of the company.</p>\n<p>That agreement, announced this morning, is for ex-U.S. rights to the migraine drug and&nbsp;could be worth up to $1.24B to Biohaven.</p>\n<p>Biohaven had more good news this morning as itsQ3 2021 earnings&nbsp;results beat expectations.</p>\n<p>Nurtec ODT sales in the quarter were $136M, a 46% increase from Q2 2021.</p>\n<p>Seeking Alpha'sQuant Rating&nbsp;for Biohaven is neutral.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven falls 15% on apparent disappointment that Pfizer deal isn't a buyout</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven falls 15% on apparent disappointment that Pfizer deal isn't a buyout\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-09 22:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3767697-biohaven-falls-15-on-apparent-disappointment-that-pfizer-deal-isnt-a-buyout><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Biohaven Pharmaceuticals(NYSE:BHVN)are down 15% in premarket trading apparently because some investors are disappointed that a Pfizer(NYSE:PFE)deal to commercialize Nurtec ODT wasn't a ...</p>\n\n<a href=\"https://seekingalpha.com/news/3767697-biohaven-falls-15-on-apparent-disappointment-that-pfizer-deal-isnt-a-buyout\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://seekingalpha.com/news/3767697-biohaven-falls-15-on-apparent-disappointment-that-pfizer-deal-isnt-a-buyout","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1122943951","content_text":"Shares of Biohaven Pharmaceuticals(NYSE:BHVN)are down 15% in premarket trading apparently because some investors are disappointed that a Pfizer(NYSE:PFE)deal to commercialize Nurtec ODT wasn't a buyout of the company.\nThat agreement, announced this morning, is for ex-U.S. rights to the migraine drug and could be worth up to $1.24B to Biohaven.\nBiohaven had more good news this morning as itsQ3 2021 earnings results beat expectations.\nNurtec ODT sales in the quarter were $136M, a 46% increase from Q2 2021.\nSeeking Alpha'sQuant Rating for Biohaven is neutral.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1044,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Biohaven falls 15% on apparent disappointment that Pfizer deal isn't a buyout

评论（1）

热议股票